Myofibroblast-Specific Inhibition of the Rho Kinase-MRTF-SRF Pathway Using Nanotechnology for the Prevention of Pulmonary Fibrosis
1Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
2Andrew M. Tager Fibrosis Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
3Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
留言 (0)